JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib.

ABSTRACT:

SUBMITTER: Ceccardi A 

PROVIDER: S-EPMC11829129 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature